Clinical Trial Update: Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of the Novartis Meningococcal B Vaccine in immunocompromised children and adolescents compared with healthy s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Novartis Meningococcal B Vaccine (Meningococcal B vaccine)

Snippet

Sponsor: Novartis | Conditions: Meningococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-02-15